Newsbenzinga
Rezolute Completes Enrollment In Open-Label Phase 3 Study Of Ersodetug In Tumor HI; Topline Data Expected In Mid-December 2026
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…